REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss-the root cause of FAP-to identify compounds ...

GI Alliance and Iterative Health have formed a strategic partnership to expand access to clinical trials across ...

Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal ...

Investigate the role of seed cycling in women's health, particularly its effects on hormonal regulation and PCOS symptom ...

Sylvie Grégoire, Chair of Abivax Board of Directors, commented: “We are delighted to welcome Dominik to the Board at such a pivotal moment for Abivax. His extensive background in global medical ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Biodesix, Inc, a leading diagnostics solutions company, and Bio-Rad Laboratories, a global leader in life science research and diagnostics products, contributed to new research findings from Friends ...

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

A proof-of-concept study will test VAS-101, a topical gel using the turmeric extract curcumin, in sickle cell disease (SCD) ...

A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as 2.3.4.4b, which has ...

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...